Loading...
Loading...
Contributors:
Dataset URI:
10.6084/m9.figshare.34477499.v2Interleukin-6 (IL-6) has been implicated in the pathogenesis of hepatocellular carcinoma (HCC) and resistance to systemic therapy. This study aimed to evaluate the prognostic value of circulating IL-6 in patients with HCC receiving systemic therapy through a systematic review and meta-analysis. A systematic literature search was conducted in PubMed, Web of Science, Scopus, and ClinicalTrials.gov from database inception to 27 July 2026. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Thirteen studies comprising 1,504 patients were included. Elevated baseline IL-6 was significantly associated with worse OS (hazard ratio [HR] = 2.29, 95%, confidence interval [CI]: 1.87–2.81; p p p p = 0.008). Evidence regarding the prognostic value of on-treatment IL-6 concentrations and longitudinal changes during therapy was limited and heterogeneous. High baseline IL-6 is associated with poor prognosis and reduced treatment response in HCC patients receiving systemic therapy, warranting further treatment-specific evaluation of its prognostic utility. www.crd.york.ac.uk/prospero identifier is CRD420261456976. What is this article about? Hepatocellular carcinoma (HCC) is the most common type of liver cancer. New drug treatments, known as systemic therapies, have improved care for people with advanced HCC. However, these treatments do not work equally well for everyone. Doctors therefore need simple tests that may help predict how a patient will respond to treatment. Interleukin-6 (IL-6) is a protein involved in chronic inflammation and cancer progression and can be measured with a routine blood test. Although many studies have investigated IL-6 in HCC, their findings have not been systematically summarized. This article reviewed and combined the available evidence to determine whether blood IL-6 levels are linked to treatment outcomes in people with HCC. What were the results? We reviewed 13 studies that included 1,504 patients. Patients with high IL-6 levels before treatment tended to have shorter survival. Their cancer also tended to worsen sooner. In addition, these patients were less likely to respond to treatment or achieve disease control. We also reviewed studies that measured IL-6 levels during treatment, but the available evidence was limited and inconsistent. What do the results mean? A blood test for IL-6 before treatment may help identify patients who are more likely to have poor outcomes. However, IL-6 is not yet ready for routine use to guide treatment decisions. Larger studies are needed to confirm these findings and determine which IL-6 levels are most useful in clinical practice.
Keyword(s):
Biological Sciences not elsewhere classified; Biotechnology; Cancer; Hepatocellular carcinoma; Immunology.
MeSH Term(s):
Grants and Funding:
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)